JOP20210215A1 - مثبط كيناز atr من bay1895344 للاستخدام في علاج مرض فرط التكاثر - Google Patents

مثبط كيناز atr من bay1895344 للاستخدام في علاج مرض فرط التكاثر

Info

Publication number
JOP20210215A1
JOP20210215A1 JOP/2021/0215A JOP20210215A JOP20210215A1 JO P20210215 A1 JOP20210215 A1 JO P20210215A1 JO P20210215 A JOP20210215 A JO P20210215A JO P20210215 A1 JOP20210215 A1 JO P20210215A1
Authority
JO
Jordan
Prior art keywords
hyper
treatment
kinase inhibitor
proliferative disease
bay1895344
Prior art date
Application number
JOP/2021/0215A
Other languages
English (en)
Inventor
Serno Peter
Margret Wengner Antje
LAGKADINOU Eleni
Assi Pardis
Krickau Dennis
WATTERS Siobhan
Wilkinson Gary
Krause Michael
Bairlein Michaela
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of JOP20210215A1 publication Critical patent/JOP20210215A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بمثبط كيناز ترنح وتوسع الشعيرات مرتبط بـِ Rad3 (ATR)، 2-[(3R)-3-مثيل مورفولين-4-يل]-4-(1-مثيل-1H-بيرازول-5-يل)-8-(1H-بيرازول-5-يل)-1، 7-نفثيريدين، للاستخدام في علاج مرض فرط التكاثر، يتميز في أنه يتم إعطاؤه بمقدار من 10 ملغم إلى 160 ملغم في اليوم، على نحو خاص بمقدار من 60 إلى 160 ملغم في اليوم. ويتعلق الاختراع الحالي أيضاً بتركيب صيدلاني يشتمل على 2-[(3R)-3-مثيل مورفولين-4-يل]-4-(1-مثيل-1H-بيرازول-5-يل)-8-(1H-بيرازول-5-يل)-1، 7-نفثيريدين بمقدار من 5 ملغم إلى 80 ملغم وسواغ مقبول صيدلانياً واحد على الأقل. ويتعلق الاختراع الحالي أيضاً بعملية لتصنيع التركيب الصيدلاني المذكور.
JOP/2021/0215A 2019-02-11 2020-02-06 مثبط كيناز atr من bay1895344 للاستخدام في علاج مرض فرط التكاثر JOP20210215A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19156399 2019-02-11
PCT/EP2020/052971 WO2020165015A1 (en) 2019-02-11 2020-02-06 The atr kinase inhibitor bay1895344 for use in the treatment of a hyper-proliferative disease

Publications (1)

Publication Number Publication Date
JOP20210215A1 true JOP20210215A1 (ar) 2023-01-30

Family

ID=65408941

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0215A JOP20210215A1 (ar) 2019-02-11 2020-02-06 مثبط كيناز atr من bay1895344 للاستخدام في علاج مرض فرط التكاثر

Country Status (17)

Country Link
US (1) US20220117973A1 (ar)
EP (1) EP3923951A1 (ar)
JP (1) JP2022521683A (ar)
KR (1) KR20210126589A (ar)
CN (1) CN113412114A (ar)
AU (1) AU2020221473A1 (ar)
BR (1) BR112021013869A2 (ar)
CA (1) CA3129346A1 (ar)
CL (1) CL2021002098A1 (ar)
EA (1) EA202192180A1 (ar)
IL (1) IL285136A (ar)
JO (1) JOP20210215A1 (ar)
MA (1) MA54928A (ar)
MX (1) MX2021009550A (ar)
SG (1) SG11202107698XA (ar)
TW (1) TW202045185A (ar)
WO (1) WO2020165015A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
JOP20190197A1 (ar) * 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153970A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine
CA3054247A1 (en) * 2017-02-24 2018-08-30 Antje Margret Wengner Combination of atr kinase inhibitors with parp inhibitors
UY37616A (es) * 2017-02-24 2018-09-28 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223

Also Published As

Publication number Publication date
JP2022521683A (ja) 2022-04-12
SG11202107698XA (en) 2021-08-30
US20220117973A1 (en) 2022-04-21
CN113412114A (zh) 2021-09-17
EA202192180A1 (ru) 2022-01-13
IL285136A (en) 2021-09-30
MA54928A (fr) 2021-12-22
CA3129346A1 (en) 2020-08-20
BR112021013869A2 (pt) 2021-09-21
CL2021002098A1 (es) 2022-02-25
TW202045185A (zh) 2020-12-16
MX2021009550A (es) 2021-09-08
EP3923951A1 (en) 2021-12-22
WO2020165015A1 (en) 2020-08-20
AU2020221473A1 (en) 2021-08-05
KR20210126589A (ko) 2021-10-20

Similar Documents

Publication Publication Date Title
AU2018203715B2 (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
JP2020514317A5 (ar)
JP2020514318A5 (ar)
JP2020505408A5 (ar)
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
MX346186B (es) Inhibidores de proteina cinasas.
MX2021009550A (es) Inhibidor de la quinasa atr para usar en el tratamiento de una enfermedad hiperproliferativa.
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
ES2938261T3 (es) Comprimido de ribociclib
WO2007092861A3 (en) Inhibitors specific of presenilin-1 and their uses
UA117506C2 (uk) Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти
JP2016529285A5 (ar)
IN2015DN00528A (ar)
JP2021038257A (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
JOP20200015A1 (ar) توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين
MX2022004197A (es) Inhibidores del factor d del complemento para administracion oral.
MX2011011687A (es) Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.
WO2018216705A1 (ja) 神経変性疾患の予防及び／又は治療剤
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
IL198630A0 (en) Pyrimidyl derivatives as protein kinase inhibitors
MD4802C1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии